Cargando…
Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France
OBJECTIVES: The objectives were 1) to elicit relative preferences for attributes of antiretroviral therapies (ART) in people living with HIV (PLWH) and 2) to explore satisfaction and adherence with current ART. PATIENTS AND METHODS: We conducted a multicenter cross-sectional study, consecutively enr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513890/ https://www.ncbi.nlm.nih.gov/pubmed/28744106 http://dx.doi.org/10.2147/PPA.S130276 |
_version_ | 1783250731061477376 |
---|---|
author | Brégigeon-Ronot, Sylvie Cheret, Antoine Cabié, André Prazuck, Thierry Volny-Anne, Alain Ali, Shehzad Bottomley, Catherine Finkielsztejn, Laurent Philippe, Caroline Parienti, Jean-Jacques |
author_facet | Brégigeon-Ronot, Sylvie Cheret, Antoine Cabié, André Prazuck, Thierry Volny-Anne, Alain Ali, Shehzad Bottomley, Catherine Finkielsztejn, Laurent Philippe, Caroline Parienti, Jean-Jacques |
author_sort | Brégigeon-Ronot, Sylvie |
collection | PubMed |
description | OBJECTIVES: The objectives were 1) to elicit relative preferences for attributes of antiretroviral therapies (ART) in people living with HIV (PLWH) and 2) to explore satisfaction and adherence with current ART. PATIENTS AND METHODS: We conducted a multicenter cross-sectional study, consecutively enrolling PLWH receiving an ART. The quantitative part estimated the strength of preference for different attributes using an online discrete choice experiment (DCE). DCE data were analyzed using a mixed logit regression model. Qualitative data were collected through individual interviews. A preliminary coding framework was developed which was then further refined and applied during thematic analysis of factors influencing satisfaction and adherence. RESULTS: A total of 101 PLWH took part in the quantitative part and 31 in the qualitative part. Over 90% had an undetectable viral load. Quantitative data revealed a strong preference for a treatment with limited drug–drug interactions, diarrhea and long-term health problems (P<0.0001), and that did not need to be taken on an empty stomach (P<0.0001). Patients also preferred to avoid problems associated with treatment failure (P<0.0001) or one that left them with a higher viral load after the first weeks of treatment (P=0.044). Differences in CD4 cell count, and pills that must be taken with food were not significant drivers of treatment choice. The strength of these attributes was reflected in the qualitative data, highlighting the importance patients place on treatment efficacy, and also suggesting that some of these attributes may impact adherence. Many factors influencing adherence and satisfaction with treatment were identified, including pill size, worry about sexual transmission and impact on social life. CONCLUSION: Most of the attributes included in this survey were important to participants when choosing an ART, in particular those related to quality of life, and these should be taken into account in order to optimize adherence and satisfaction. |
format | Online Article Text |
id | pubmed-5513890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55138902017-07-25 Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France Brégigeon-Ronot, Sylvie Cheret, Antoine Cabié, André Prazuck, Thierry Volny-Anne, Alain Ali, Shehzad Bottomley, Catherine Finkielsztejn, Laurent Philippe, Caroline Parienti, Jean-Jacques Patient Prefer Adherence Original Research OBJECTIVES: The objectives were 1) to elicit relative preferences for attributes of antiretroviral therapies (ART) in people living with HIV (PLWH) and 2) to explore satisfaction and adherence with current ART. PATIENTS AND METHODS: We conducted a multicenter cross-sectional study, consecutively enrolling PLWH receiving an ART. The quantitative part estimated the strength of preference for different attributes using an online discrete choice experiment (DCE). DCE data were analyzed using a mixed logit regression model. Qualitative data were collected through individual interviews. A preliminary coding framework was developed which was then further refined and applied during thematic analysis of factors influencing satisfaction and adherence. RESULTS: A total of 101 PLWH took part in the quantitative part and 31 in the qualitative part. Over 90% had an undetectable viral load. Quantitative data revealed a strong preference for a treatment with limited drug–drug interactions, diarrhea and long-term health problems (P<0.0001), and that did not need to be taken on an empty stomach (P<0.0001). Patients also preferred to avoid problems associated with treatment failure (P<0.0001) or one that left them with a higher viral load after the first weeks of treatment (P=0.044). Differences in CD4 cell count, and pills that must be taken with food were not significant drivers of treatment choice. The strength of these attributes was reflected in the qualitative data, highlighting the importance patients place on treatment efficacy, and also suggesting that some of these attributes may impact adherence. Many factors influencing adherence and satisfaction with treatment were identified, including pill size, worry about sexual transmission and impact on social life. CONCLUSION: Most of the attributes included in this survey were important to participants when choosing an ART, in particular those related to quality of life, and these should be taken into account in order to optimize adherence and satisfaction. Dove Medical Press 2017-07-10 /pmc/articles/PMC5513890/ /pubmed/28744106 http://dx.doi.org/10.2147/PPA.S130276 Text en © 2017 Brégigeon-Ronot et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Brégigeon-Ronot, Sylvie Cheret, Antoine Cabié, André Prazuck, Thierry Volny-Anne, Alain Ali, Shehzad Bottomley, Catherine Finkielsztejn, Laurent Philippe, Caroline Parienti, Jean-Jacques Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France |
title | Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France |
title_full | Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France |
title_fullStr | Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France |
title_full_unstemmed | Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France |
title_short | Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France |
title_sort | evaluating patient preference and satisfaction for human immunodeficiency virus therapy in france |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513890/ https://www.ncbi.nlm.nih.gov/pubmed/28744106 http://dx.doi.org/10.2147/PPA.S130276 |
work_keys_str_mv | AT bregigeonronotsylvie evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT cheretantoine evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT cabieandre evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT prazuckthierry evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT volnyannealain evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT alishehzad evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT bottomleycatherine evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT finkielsztejnlaurent evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT philippecaroline evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance AT parientijeanjacques evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance |